Clinical Observation Of Kangfuxin Liquid And Rabeprazole Combined Treatment For Alcohol Related Gastric Mucosal Injury

Objective:To observe the therapeutic effects of Kangfuxin Liquid andrabeprazole combined treatment of alcohol related gastric mucosal injury.Methods: This study selected303cases adult (18~60years old) patients treatedin the outpatient and inpatient Department of Gastroenterology of the SecondHospital of Jilin University from May2012to November2013,and who weredefined as alcohol related gastric mucosal injury by asking personal case history andgastroscopy examination, three of the patients with symptoms improved refused toreview, the remaining300cases including male273cases and female27cases, theaverage age was36±7.28years old. There are36cases alcohol related acutegastritis,78cases alcohol related peptic ulcer,186cases alcohol related chronicgastritis of acute attack patients. According to the administration of different,patients were randomly divided into3groups: Kangfuxin Liquid combined withrabeprazole group (group A),L-Glutamine and Sodium Gualenate Granulescombined with rabeprazole group (group B)and rabeprazole alone group (groupC),each group of100people. Group A took rabeprazole20mg,1times/d andKangfuxin Liquid10ml，3times/d; Group B took rabeprazole20mg,1times/d andL-Glutamine and Sodium Gualenate Granules0.67g,3times/d; Group C tookrabeprazole20mg,1times/d. Acute gastritis patients therapy for2~4weeks, thetreatment of other diseases group were for4~6weeks. Follow-up or reexaminegastroscopy for patients at the end of the first, the second, the fourth and the sixthweeks of treatment. Through the comparison of the improvement of clinicalsymptoms after1week of treatment and each review endoscopic mucosal healing situation and speed of these three groups, to observe the curative effects ofKangfuxin Liquid and rabeprazole combined treatment for alcohol related gastricmucosal injury. Measurement data were subjected to t test and enumeration data toX2test, P <0.05is considered the difference was statistically significant.Rusults:1. Chronic gastritis of acute attack groupClinical symptoms,(abdominal pain, abdominal discomfort, nausea andvomiting, acid regurgitation and heartburn, hematemesis, black stool) remission ratewere shown in table5.1.1. In the abdominal pain and abdominal discomfort，theremission rate of group A was slightly higher than that of group B, group B washigher than group C, but there were no significance difference between the threegroups (P>0.05). The remission rates of other symptoms of three groups weresimilar, and there were no significant difference (P>0.05).All patients were rechecked by gastroscopy regularly after treatment，detailshown in table5.1.2.Of the same stage after treatment,the mucosal lesions,endoscopic improvement rate of group A were higher than those in C group, thedifference was significant (P <0.01). Differences between group A and group B as wellas group B and group C were small, but statistically significant (0.01<P<0.05).Pathology: pathological improvement situation of patients of the three groupsafter treatment were shown in table5.1.3, the differences between three groups hadno statistical significance (P <0.05).2. Peptic ulcer groupClinical symptoms,(abdominal pain, abdominal discomfort, nausea andvomiting, acid regurgitation and heartburn, hematemesis, black stool) remission ratesof patients in three groups were shown in table5.2.1.In abdominal pain andabdominal discomfort，relief rate of group A was higher than that of group B，groupB higher than group C, but not much differences between the three groups (P>0.05).the other same symptoms,remission rates had no statistical significance (P>0.05).All patients were rechecked by gastroscopy regularly after treatment, endoscopic mucosal lesions,improvement situation of three groups of the same stagewere shown in table5.2.2.The improvement rate of group A were significantlyhigher than those in C group (P<0.01); differences between group A and group B,group B and group C were small, but both were statistically significant(0.01<P<0.05). After2weeks of treatment,96.30%endoscopic mucosal lesions inpatients of group A had improved,4weeks later, all healed; after2weeks,treatment,the improvement rate of group B was62.50%,79.17%after4weeks, and allhealed after6weeks; the improvement rate of group C after2weeks was40.74%,51.86%after4weeks, after6weeks completely reached healing, suggesting group Ahealed faster than group B (0.01<P<0.05), and more obvious compared with thegroup C (P<0.01), group B healed slightly faster than group C (P<0.05).Pathology: pathological improvement situation of patients of the three groupsafter treatment were shown in table5.2.3, the differences between three groups hadno statistical significance (P <0.05).3. Acute gastritis groupClinical symptoms,(abdominal pain, abdominal discomfort, nausea andvomiting, acid regurgitation and heartburn, hematemesis, black stool)remission rateswere shown in table5.3.1. the difference of all clinical symptoms between the threegroups had no statistical significance (P<0.05).Recheck all patients by gastroscopy after1weeks,treatment, detail shown intable5.3.2. The remission rates of group A and group B were both100%, group C91.67%, the differences were not significant(P>0.05).Pathological changes after2weeks,treatment of three groups were shown intable5.3.3, the differences had no statistical significance (P<0.05).4. The total efficiencyClinical symptoms (abdominal pain, abdominal discomfort, nausea andvomiting, acid regurgitation and heartburn, hematemesis, black stool) of three groupswere shown in5.4.1. Remission rates of abdominal pain, abdominal discomfort ofgroup A were higher than those in group B, and group B higher than group C, but differences between each of the same clinical symptoms had no statisticalsignificance (P>0.05).Remission rates under gastroscope were shown in table5.4.2.After4weeks,treatment, the remission rate under gastroscope of group A was100%, comparedwith group B (87.59%), there were no significant difference. Group B comparinggroup C and Group A comparing group C, the differences were both obvious(P<0.01). After treatment of the same period, differences of improvement rate undergastroscope between three groups were all statistically significant (P<0.01).Pathology: Pathological improvement rates of three groups after treatment wereshown in table5.4.3, the difference between three groups had no statisticalsignificance (P<0.05).Conclusion：1. Kangfuxin Liquid and rabeprazole combined treatment can promote mucosalhealing of alcohol related chronic gastritis of acute attack and peptic ulcer patients,shorten the mucosal healing time, improve the treatment efficiency, compared withthe simple application of rabeprazole therapy or L-Glutamine and Sodium GualenateGranules and rabeprazole combined treatment, the difference had statisticalsignificance，thus New recovery liquid for the treatment of chronic gastritis of acuteattack and peptic ulcer is worth clinical promotion. But in clinical symptoms, therewere no obvious difference compared with the other two groups.2. For acute gastritis, the clinical symptoms,remission rates, endoscopicmucosal improving speed and healing time and pathological changes of KangfuxinLiquid and rabeprazole combined treatment group had no statistically significantdifference Compared with Kangfuxin Liquid treated group or L-Glutamine andSodium Gualenate Granules and rabeprazole combined treatment group.